

1 **A booster dose of an inactivated SARS-CoV-2 vaccine increases**
2 **neutralizing antibodies and T cells that recognize Delta and**
3 **Omicron variants of concern.**

4 Bárbara M Schultz^{1,#}, Felipe Melo-González^{1,#}, Luisa F Duarte^{1,#}, Nicolás MS
5 Gálvez^{1,#}, Gaspar A Pacheco^{1,#}, Jorge A Soto^{1,#}, Roslye V Berríos-Rojas^{1,2}, Liliana
6 A González^{1,2}, Daniela Moreno-Tapia^{1,2}, Daniela Rivera-Pérez^{1,2}, Mariana Ríos^{1,2},
7 Yaneisi Vázquez^{1,2}, Guillermo Hoppe-Elsholz^{1,2}, Omar P Vallejos^{1,2}, Carolina
8 Iturriaga³, Marcela Urzua³, María S Navarrete⁴, Álvaro Rojas⁴, Rodrigo Fasce⁵,
9 Jorge Fernández⁵, Judith Mora⁵, Eugenio Ramírez⁵, Aracelly Gaete-Argel^{1,6},
10 Mónica Acevedo^{1,6}, Fernando Valiente-Echeverría^{1,6}, Ricardo Soto-Rifo^{1,6}, Daniela
11 Weiskopf⁷, Alba Grifoni⁷, Alessandro Sette^{7,8}, Gang Zeng⁹, Weining Meng⁹,
12 CoronaVac03CL Study Group, José V González-Aramundiz¹⁰, Pablo A
13 González^{1,2}, Katia Abarca^{1,3}, Alexis M Kalergis^{*1,2,11}, Susan M Bueno^{*1,2}

14

15 **Affiliations:**

16 ¹Millennium Institute on Immunology and Immunotherapy, Santiago, Chile.

17 ²Departamento de Genética Molecular y Microbiología, Facultad de Ciencias
18 Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile.

19 ³Departamento de Enfermedades Infecciosas e Inmunología Pediátrica, División
20 de Pediatría, Escuela de Medicina, Pontificia Universidad Católica de Chile,
21 Santiago, Chile. ⁴Departamento de Enfermedades Infecciosas del Adulto, División

22 de Medicina, Escuela de Medicina, Pontificia Universidad Católica de Chile,
23 Santiago, Chile. ⁵Departamento de Laboratorio Biomédico, Instituto de Salud

24 Pública de Chile. ⁶Laboratorio de Virología Molecular y Celular, Programa de
25 Virología, Instituto de Ciencias Biomédicas, Facultad de Medicina, Universidad de
26 Chile, Santiago, Chile. ⁷Center for Infectious Disease and Vaccine Research, La
27 Jolla Institute for Immunology (LJI), La Jolla, CA 92037, USA. ⁸Department of
28 Medicine, Division of Infectious Diseases and Global Public Health, University of
29 California, San Diego (UCSD), La Jolla, CA 92037, USA. ⁹Sinovac Biotech, Beijing,
30 China. ¹⁰Departamento de Farmacia, Facultad de Química y de Farmacia,
31 Pontificia Universidad Católica de Chile, Santiago, Chile. ¹¹Departamento de
32 Endocrinología, Facultad de Medicina, Escuela de Medicina, Pontificia Universidad
33 Católica de Chile, Santiago, Chile.

34

35 # These authors contributed equally to this work.

36

37 *Corresponding authors.

38 **Keywords:**

39 CoronaVac; Phase 3 clinical trial; SARS-CoV-2; COVID-19; inactivated vaccine,
40 Booster dose.

41

42 **Abstract**

43 **Background:** CoronaVac[®] is an inactivated SARS-CoV-2 vaccine approved by the
44 World Health Organization. Previous studies reported increased levels of
45 neutralizing antibodies and specific T cells two- and four-weeks after two doses of
46 CoronaVac[®], but the levels of neutralizing antibodies are reduced at six to eight
47 months after two doses. Here we report the effect of a booster dose of CoronaVac[®]
48 on the anti-SARS-CoV-2 immune response generated against variants of concern
49 (VOC) Delta and Omicron in adults participating in a phase 3 clinical trial in Chile.

50 **Methods:** Volunteers immunized with two doses of CoronaVac[®] in a four-week
51 interval received a booster dose of the same vaccine between twenty-four and
52 thirty weeks after the 2nd dose. Four weeks after the booster dose, neutralizing
53 antibodies and T cell responses were measured. Neutralization capacities and T
54 cell activation against VOC Delta and Omicron were detected at four weeks after
55 the booster dose. **Findings:** We observed a significant increase in neutralizing
56 antibodies at four weeks after the booster dose. We also observed an increase in
57 CD4⁺ T cells numbers over time, reaching a peak at four weeks after the booster
58 dose. Furthermore, neutralizing antibodies and SARS-CoV-2 specific T cells
59 induced by the booster showed activity against VOC Delta and Omicron.

60 **Interpretation:** Our results show that a booster dose of CoronaVac[®] increases the
61 anti-SARS-CoV-2 humoral and cellular immune responses in adults. Immunity
62 induced by a booster dose of CoronaVac[®] is active against VOC, suggesting an
63 effective protection.

64

65 **Background**

66 The ongoing pandemic caused by severe acute respiratory syndrome
67 coronavirus-2 (SARS-CoV-2) has promoted the rapid development of safe,
68 immunogenic, and effective vaccines against SARS-CoV-2 to be used by the
69 general population, which have successfully reduced the transmission of the
70 disease burden. CoronaVac® is an inactivated SARS-CoV-2 vaccine developed by
71 Sinovac Life Sciences Co., Ltd. (Beijing, China) and is among the current vaccines
72 approved by the World Health Organization (WHO) to combat coronavirus disease
73 2019 (COVID-19) and one of the most used vaccines worldwide^{1,2}. Phase I/II
74 clinical trials in China demonstrated that this vaccine induces cellular and humoral
75 response upon immunization³⁻⁵. Furthermore, the ongoing phase 3 clinical trial in
76 Chile has described an increase in the levels of IgG and neutralizing antibodies in
77 adults aged 18-59 years and ≥ 60 years two- and four-weeks after the second dose
78 of CoronaVac®⁵⁶. In addition, this vaccination promotes the activation of a T cell
79 immune response against SARS-CoV-2 antigens in a 0-14 immunization schedule
80 ⁵ (two-weeks interval), being an effective vaccine to prevent COVID-19^{7,8}. In Chile,
81 93.7% of the target population has received a first vaccine dose, and 91.4% were
82 fully vaccinated with CoronaVac® on December 10th of 2021 in a 0-28 days
83 vaccination schedule⁹. Although this primary immunization schedule induces
84 neutralizing antibody present in the serum of vaccinated people¹⁰, these titers
85 decrease in time^{6,11,12} and have lower levels of neutralization against highly
86 transmissible variants of concern (VOC) as compared to the original vaccine strain,
87 potentially decreasing the effectiveness of these vaccines as new variants emerge

88 ¹³⁻¹⁷. For these reasons, the use of booster doses was approved in Chile in August
89 2021 in Chile for high-risk populations and adults at five months after
90 administration of the second dose ¹⁸. In this sense, a report published in October
91 2021 in Chile, showed that the effectiveness of CoronaVac[®] against COVID-19
92 increase from 56% to 80% fourteen days after the application of the booster dose
93 ¹⁹. Notably, a previous study performed in adults aged 18-59 years old
94 demonstrated that a booster dose of CoronaVac[®], applied six months after the first
95 dose to individuals that previously received two doses of this vaccine, increased
96 the levels of antibodies 3-5-fold as compared to the levels observed four weeks
97 after the second dose ¹². Here, we further extend these findings by reporting the
98 levels of neutralizing antibodies and specific T cells against SARS-CoV-2 and its
99 activity against VOC Delta and Omicron in adults ≥ 18 years old that participated in
100 the phase 3 clinical trial carried out in Chile, who were vaccinated in a 0-28-days
101 vaccination schedule and received a booster dose five months after the second
102 dose.

103

104 **Materials and methods**

105 **Volunteers and sample collection**

106 Blood samples were obtained from volunteers recruited in the clinical trial
107 CoronaVac03CL (clinicaltrials.gov #NCT04651790) carried out in Chile starting in
108 November 2020. The Institutional Scientific Ethical Committee of Health Sciences
109 reviewed and approved the study protocol at the Pontificia Universidad Católica de
110 Chile (#200708006). Trial execution was approved by the Chilean Public Health
111 Institute (#24204/20) and was conducted according to the current Tripartite

112 Guidelines for Good Clinical Practices, the Declaration of Helsinki ²⁰, and local
113 regulations. Informed consent was obtained from all volunteers upon enrollment.
114 Volunteers receive two doses of CoronaVac[®] (3 µg or 600SU of inactivated SARS-
115 CoV-2 inactivated along with alum adjuvant) in a four-week interval (0-28-day
116 immunization schedule) and then a booster dose five months after the second
117 dose. A complete inclusion and exclusion criteria list have been reported ⁵. On
118 November 11th, 2021, one hundred and eighty-six volunteers in the immunogenicity
119 branch received the booster dose. The antibody and cell mediated immune
120 responses were evaluated volunteers that had completed all their previous visits in
121 one of the centers of the study (**Figure 1A**). Blood samples were obtained from all
122 the volunteers before administration of the first dose (pre-immune), two, four, and
123 twenty weeks (or five months) after the second dose, and four weeks after the
124 booster dose (**Figure 1B**).

125 **Procedures**

126 The presence of antibodies against RBD with neutralizing capacities were
127 measured in sera from seventy-seven volunteers that had completed all their study
128 visits, including one month after the booster dose of CoronaVac[®]. The neutralizing
129 capacities of circulating antibodies were evaluated by a surrogate virus
130 neutralization test (sVNT) (Genscript Cat#L00847-A). Samples were two-fold
131 serially diluted starting at a 4-fold dilution until reaching a 512-fold dilution. Assays
132 were performed according to the instructions of the manufacturer and as reported
133 previously ⁵. Neutralizing antibody titers were determined as the last fold dilution in
134 which the interaction between hACE2 and RBD was inhibited by 30% or more.
135 Samples with a percentage of inhibition $\leq 30\%$ at the lowest dilution (1:4) were

136 assigned as seronegative with a titer of 2. A sample was considered seropositive
137 when its titer was higher than the pre-immune titer. The percentage of inhibition
138 was determined as: $100 * [\text{OD}_{450\text{nm}} \text{ value of negative control} - \text{OD}_{450\text{nm}} \text{ value of}$
139 $\text{sample}] / [\text{OD}_{450\text{nm}} \text{ of negative control}]$. A standard curve was used to plot the
140 neutralization response in the samples as international units (IU) using the WHO
141 International Standard for SARS-CoV-2 antibody (NIBSC code 20/136), which was
142 prepared according to the instructions of the manufacturer ²¹. Data were analyzed
143 using a sigmoidal curve model with a logarithm transformation of the concentration,
144 and the final concentration for each sample was the average of the product of the
145 interpolated IU from the standard curve and the sample dilution factor required to
146 reach the OD450 value that falls within the linear range determined for each
147 sample. Samples with undetermined concentration at the lowest dilution tested
148 (1:4) were assigned to the lower limit of quantification (16.4 IU). The Geometric
149 Mean Units (GMU) and titers (GMT) were represented in **Figure 2** and
150 **Supplementary Figure 1**, respectively. **Table 2** shows comparisons among the
151 visits.

152 Conventional virus neutralization tests (cVNT) were performed in sixty-two
153 of the previous seventy-seven volunteers and evaluated as previously reported ⁵.
154 Briefly, Vero E6 cells were infected with a SARS-CoV-2 strain obtained by viral
155 isolation in tissue cultures (33782CL-SARS-CoV-2 strain, D614G variant).
156 Neutralization assays were carried out by the reduction of cytopathic effect (CPE)
157 in Vero E6 cells (ATCC CRL-1586). The titer of neutralizing antibodies was defined
158 as the highest serum dilution that neutralized virus infection, at which the CPE was
159 absent as compared with the virus control wells (cells with CPE). Vero E6 cells

160 were seeded in 96-well plates (4×10^4 cells/well). For neutralization assays, 100 μ L
161 of 33782CL-SARS-CoV-2 (at a dose of 100 TCID₅₀) were incubated with serial
162 dilutions of heat-inactivated sera samples (dilutions of 1:4, 1:8, 1:16, 1:32, 1:64,
163 1:128, 1:256, and 1:512) from participants for 1h at 37 °C. Cytopathic effect on
164 Vero E6 cells was analyzed 7 days after infection.

165 A pseudotyped virus neutralization test (pVNT) assay was performed to
166 assess the capacity of the antibodies against SARS-CoV-2 VOC in samples from
167 thirty volunteers of the seventy-seven previously analyzed by sVNT. As previously
168 reported ¹⁴, a HIV-1 backbone expressing firefly luciferase as a reporter gene and
169 pseudotyped with the SARS-CoV-2 spike glycoproteins (HIV-1-S Δ 19) from from
170 lineage B.1 (D614G) or variants Delta (T19R, del157/158, L452R, T478K, D614G,
171 P681R, D950N) and Omicron (A67V, Δ H69-V70, T95I, Y145D, Δ G142 -V143-
172 Y144, Δ N211, EPE 213-214, G339D, S371L, S373P, S375F, K417N, N440K,
173 G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, T547K, D614G,
174 H655Y, N679K, P681H, N764K, N865K, Q954H, N969K, L981F) was prepared as
175 previously described ²². Serum samples were two-fold diluted starting at 1:10 or 1:4
176 and the estimation of the ID80 was obtained using a 4-parameter nonlinear
177 regression curve fit measured as the percent of neutralization determined by the
178 difference in average relative light units (RLU) between test samples and
179 pseudotyped virus controls. Also, cVNT assays were performed to assess the
180 capacity of the antibodies against SARS-CoV-2 Delta variant in samples from
181 nineteen volunteers of the seventy-seven previously analyzed by sVNT.

182 ELISPOT and flow cytometry assays were performed to evaluate the cellular
183 immune response in forty volunteers of the seventy-seven previously analyzed

184 **(Figure 1A)**, stimulating PBMCs with four Mega Pools (MPs) of peptides derived
185 from the proteome of SARS-CoV-2 ²³: peptides from the S protein of SARS-CoV-2
186 (MP-S), the remaining proteins of the viral particle (excluding S protein peptides)
187 (MP-R), and shorter peptides from the whole proteome of SARS-CoV-2 (MP-CD8-
188 A and MP-CD8-B) ²³. Thirty of the previously analyzed volunteers were also
189 stimulated with three Mega Pools (MP) of VOC, provided by La Jolla Institute for
190 Immunology. MP derived from the S protein of SARS-CoV-2 WT, SARS-CoV-2
191 B1.617.2 MP 4326 (Delta variant), and SARS-CoV-2 B1.1.529 MP 4359 (Omicron
192 variant) ¹⁴ were used to evaluate T cell activation at four weeks after the booster
193 dose. Positive and negative controls were held for each assay. The number of Spot
194 Forming Cells (SFC) for interferon gamma (IFN- γ) were determined by ELISPOT
195 and the expression of Activation-Induced Markers (AIM) by T cells was evaluated
196 by flow cytometry. Assays were performed according to the instructions of the
197 manufacturer and as reported previously ⁵. Further details on the ELISPOT assay,
198 antibodies used for flow cytometry, and the respective protocols can be found in
199 the Supplementary information and **Supplementary Table 1**.

200 Interleukin 2 (IL-2) and IFN- γ secretion were evaluated in the supernatants
201 of twenty-two volunteers previously stimulated for 20h with SARS-CoV-2 MP of
202 peptides derived from the Spike protein of VOC, using a Luminex 200 xMap
203 multiplex system (Luminex Corporation, Austin, TX). The limit of detection for the
204 cytokine measured ranged from 4.2 to 13,390 pg/mL, according to manufacturer's
205 instructions. Further experimental details can be found in **Supplementary**
206 **Information**.

207

208 **Statistical analyses**

209 Statistical differences for the immunogenicity results considered repeated
210 measures ANOVA with the Geisser-Greenhouse correction and Dunnet's *a*
211 *posteriori* multiple tests to compare between the booster dose and the other visits.
212 Analyses were performed over the base 10 logarithms of the data for neutralizing
213 antibody by sVNT, cVNT and pVNT. Cellular immune responses were analyzed by
214 a Friedman test for repeated measures for ELISPOT and flow cytometry for the
215 comparisons between booster dose and the other visits. Secretion of cytokines
216 were compared between the secretion induced by the WT strain against the VOC
217 Delta and Omicron by repeated measures ANOVA. The significance level was set
218 at 0.05 for all the analyses. All data were analyzed with GraphPad Prism 9.0.1.

219

220 **Results**

221 **A booster dose of CoronaVac[®] induces a significant increase in**
222 **antibody titers with neutralizing capacity in adults.**

223 One hundred and eighty-six volunteers from the immunogenicity branch that
224 received a booster dose of the CoronaVac[®] were included in this study. The first
225 dose of the vaccine was inoculated from January to March of 2021, and the second
226 dose was inoculated 28 days after the first one. The neutralizing capacity of serum
227 antibodies was evaluated in seventy-seven and sixty-two volunteers by sVNT and
228 cVNT, respectively, at the five different time-points indicated in **Figure 1B**.

229 As shown in **Figures 2A and D**, the peak level of antibodies with
230 neutralizing capacity in the total population evaluated, tested by sVNT and cVNT,

231 is reached at two weeks after the second dose (GMU 168.0, 95% CI=19.5-34.2
232 and GMT, 95% CI=) and four weeks after the second dose (GMU 124.8, 95%
233 CI=96.3-161.7 and GMT 13.5, 95% CI=9.6-19.2). However, this neutralizing
234 capacity significantly decreased twenty weeks after the second dose (GMU 39.0,
235 95% CI=32.4-47.0 and GMT 8.3, 95% CI=9.6-19.2), which is in line with previous
236 reports where the immunity against SARS-CoV-2 wanes six months after infection
237 or vaccination ^{24,25}. After the booster dose, the neutralizing capacity of the
238 antibodies increased even more than the one reported two weeks after the second
239 dose (GMU 499.0, 95% CI=370.6-673.0 and GMT 89.5 ± 64.0-125.2). Overall, we
240 observed that four weeks after the booster dose the neutralizing capacity increased
241 more than 12-fold (sVNT) and 10-fold (cVNT) as compared to the response at
242 twenty weeks after the second dose, and almost 3-fold as compared to two weeks
243 after the second dose (**Figures 2A and D**).

244 In adults 18-59 years old, the neutralizing capacity of circulating antibodies
245 tested by sVNT and cVNT (**Figures 2B and E**, respectively) reached its maximum
246 four weeks after the booster dose (GMU 918.8, 95% CI=623.4-1354 and 176.9,
247 95% CI=111.7-280.1) increasing more than 18- and 12-fold as compared to five
248 months after the second dose (GMU 48.9, 95% CI=37.6-63.5 and GMT 14.2, 95%
249 CI=7.1-28.4) and more than 4-fold as compared to two weeks after the second
250 dose (GMU 220.2, 95% CI=150.7-321.7 and GMT 17.5, 95% CI=9.8-31.3)
251 (**Figures 2B and E**). The seropositivity rate in this group reached 100% at four
252 weeks after the booster dose (**Table 2**). On the other hand, 53.2% of the total
253 volunteers analyzed here were adults ≥60 years. In this group, the same tendency

254 was observed, as seen in **Figure 2C and F**, observing an increase in the level of
255 neutralizing antibodies evaluated by both techniques of more than 9-fold at four
256 weeks after the booster dose (GMU 300.5, 95% CI=203.5-443.6 and GMT 47.3,
257 95% CI=32.1-69.5) as compared to the response observed twenty weeks after the
258 second dose (GMU 32.4, 95% CI=25.1-41.8 and GMT 5.0, 95% CI=3.5-7.0).
259 Equivalent to the 18-59 years old group, the seropositivity rate in this age group
260 reached 100% four weeks after the booster dose (**Table 2**). The seropositivity rate
261 achieved at four weeks after the booster dose was the highest when compared
262 with the other visits in this study in the total vaccinated group and in both groups
263 analyzed.

264

265 **A booster dose of CoronaVac[®] induces a robust cellular immune**
266 **response in adults.**

267 The cellular responses following a booster dose of CoronaVac[®] were
268 evaluated in 40 volunteers. We observed that CD4⁺ T cell activation was increased
269 twenty weeks after the second dose as compared to the other time points in both
270 age groups, suggesting that CoronaVac[®] can stimulate CD4⁺ T cell responses that
271 are sustained over time (**Figure 3A-C**). Importantly, we observed a significantly
272 further increase in CD4⁺ T cell activation in both age groups following the booster
273 dose, as compared to the pre-immune sample and samples obtained at two and
274 four weeks after the second dose (**Figure 3A-C**). However, this difference was not
275 significant as compared to the sample obtained twenty weeks after the second
276 dose (**Figure 3A-C**). Moreover, we did not observe a significant increase in the
277 expression of AIM by CD8⁺ T cells following the booster dose as compared to any

278 other time point, suggesting that specific CD8⁺ T cell responses induced by
279 CoronaVac[®] are not detected with the current methodologies, even after a third
280 dose (**Supp. Figure 2A and C**). Accordingly, we observed an increase in IFN- γ
281 production upon stimulation with mega-pools of peptides (MPs) S and R by
282 ELISPOT at four weeks after the booster dose for both groups, as compared to the
283 pre-immune sample (**Figure 3D-F**). As in the case of flow cytometry, we did not
284 observe significant increase of IFN- γ ⁺ SFCs upon stimulation with CD8 MPs at any
285 time point (**Supp. Figure 2**). These results suggest that although humoral
286 responses decrease over time following vaccination with CoronaVac[®], CD4⁺ T cell
287 responses remain significantly increased as compared to pre-immune samples and
288 the booster dose promotes a small increase both IFN- γ production and CD4⁺ T cell
289 activation that is not significantly different as compared to the levels observed 20
290 weeks after the second dose.

291

292 **Neutralizing antibodies and specific T cells induced by a booster dose** 293 **of CoronaVac[®] recognize Delta and Omicron variants of SARS-CoV-2.**

294 As we observed that the neutralization capacity and the T cell responses
295 increased significantly with the booster dose and knowing that vaccinated
296 volunteers exhibit decreased neutralization against VOC¹⁴, we proceeded to
297 evaluate the neutralizing capacities of antibodies in the serum from thirty booster-
298 vaccinated individuals in pseudotyped virus neutralization test (pVNT) assay
299 against two variants of concern of SARS-CoV-2, comparing with the level obtained
300 for the D614G SARS-CoV-2 variant (B.1 lineage, **Figure 4A-B**). We observed that

301 the titers of antibodies with neutralizing capacities against Delta and Omicron
302 variant show a significant reduction as compared to the levels achieved for the
303 D61G variant (D614G: GMT 241.8, CI=155.7-375.6, Delta: 159.2, CI=99.1-256.0
304 and Omicron: GMT 50.7, CI=30.4-84.8), with a reduction of 1.5 for Delta and 4.8
305 for Omicron (**Figure 4A**). However, when we compared the changes in
306 seropositivity for Delta and Omicron (**Figure 4B**), we observed a 93% and 76.7%,
307 respectively, following the booster dose (**Table 3**). Neutralization assays against
308 Delta variant with a cVNT in a different group of nineteen volunteers also show that
309 antibodies induced four weeks after the booster dose have reduced capacity to
310 neutralize this VOC (**Supp Figure 4A**), although the seropositivity rate observed is
311 84% (**Supp Figure 4B**).

312 The cellular responses for VOC following a booster dose of CoronaVac®
313 were also evaluated in thirty volunteers using MPs of peptides derived from the
314 Spike protein of Delta and Omicron variants. We observed equivalent numbers of
315 AIM by CD4⁺ T cells after four weeks of the booster dose upon stimulation with MP-
316 S of SARS-CoV-2 WT, Delta, or Omicron variant (**Figure 5A**), with no significant
317 differences between the response against the MP-S of the variants as compared to
318 the MP-S of the WT strain. IFN- γ secreting T cells were also analyzed in these
319 samples and no differences were observed (**Figure 5B**). We also quantified the
320 production of different cytokines in the supernatant of PBMCs stimulated with the
321 MP-s of WT, Delta, and Omicron variants, observing that at four weeks after the
322 booster dose the stimulated cells secrete equivalent levels of IL-2 and IFN- γ
323 (**Figure Supp 3**). These results suggest that although the humoral response

324 measured as neutralization capacities and seroconversion against these VOC is
325 lower as compared to the humoral response against the D614G strain, the cellular
326 responses against SARS-CoV-2 VOC is equivalent to the responses elicited by the
327 wild type strain in volunteers vaccinated with booster dose.

328

329 **Discussion**

330 In this report we evaluated the humoral and cellular immune response
331 generated four weeks after the application of a booster dose of inactivated
332 CoronaVac® vaccine in a cohort of volunteers enrolled in the phase 3 clinical trial
333 held in Chile. The data reported here showed that although there was an adequate
334 humoral response after two doses of CoronaVac®, with a 65.9% of effectiveness in
335 preventing COVID-19⁸, both the sVNT and cVNT assays showed a decrease in
336 the GMT of neutralizing capacities of circulating antibodies against SARS-CoV2
337 twenty weeks after the second dose (**Figure 2**). Due to this decrease in
338 neutralizing capacities, a booster dose of CoronaVac® was evaluated in a clinical
339 study in China, showing promising results in enhanced humoral immune
340 responses^{12,26}. The evaluation of the immune response reported here shows that
341 after the booster dose, the neutralizing titers and seroconversion rates increase in
342 the whole group, to a higher extent than two weeks after the second dose, where
343 the peak in neutralization was previously observed, which is in line with the
344 observed by *Clemens et al.*,¹⁵. Also, we observed a steady activation of the CD4⁺
345 T cells and secretion of IFN- γ during the time-points evaluated (**Figure 3**).

346 Since the neutralizing antibody titers correlated with protection against
347 SARS-CoV-2 infection ¹⁰, these results likely imply a better outcome and protection
348 against COVID-19, as reported in previous studies performed in Israel that showed
349 a decrease in the transmission and the disease severity disease by this virus
350 twelve or more days after booster inoculation. In Chile, the effectiveness and
351 prevention in hospitalization increased when assessed fourteen days after the
352 booster dose of CoronaVac[®] ^{19,27}. Another study, performed with a booster dose of
353 CoronaVac[®], showed that an additional dose result in good neutralization capacity
354 against parental SARS-CoV-2 and against Delta variant four weeks after the
355 booster dose, generating a long-lasting humoral response, which was due to an
356 enhancement of the memory immune response generated by B cells ²⁶.

357 Adults ≥ 60 years old produced lower levels of antibodies with neutralizing
358 capacities than the whole group during this study, which was also described
359 previously (**Figure 2C and F**) ⁵. This result is in line with previous data reported for
360 a population vaccinated in Chile ⁶, among hospital workers who received two
361 doses of CoronaVac[®] ²⁸, and in a study with the mRNA-1273 vaccine ²⁹. In this
362 sense, our results are equivalent to those described in a phase I/II of the clinical
363 trial performed with CoronaVac[®] in China, showing that the neutralizing antibody
364 titers in this group decreased at five months after the second dose and that a
365 booster dose is required 6-8 months after the first vaccination to rapidly increase
366 and maintain the neutralizing antibody titers ³⁰.

367 In the case of the T cell response (**Figure 3**), other studies have shown that
368 Pfizer BNT162b2 and mRNA-1273 induce durable CD4⁺ T cell activation and
369 cytokine production up to six months following vaccination, but it remains to be

370 elucidated whether expression of AIM by CD4⁺ T cells and cytokine production
371 further increase following a booster dose with these vaccines ^{31,32}. Here, we
372 observed that the activation of CD4⁺ T cells and IFN- γ production stays increased
373 up to twenty weeks after the second dose, and after the booster dose both
374 parameters increased in the 18-59 years old group and was maintained at the
375 levels observed twenty weeks after the second dose in adults ≥ 60 years old. In
376 contrast to BNT162b2 and mRNA-1273 vaccines, CoronaVac[®] delivers not only
377 the Spike protein upon immunization but also other viral antigens, which may
378 explain why vaccinated individuals still display AIM⁺ CD4⁺ T cells five months after
379 the second dose, regardless of a third dose.

380 When the neutralization capacity analyzed by pVNT of the VOC Delta and
381 Omicron was evaluated four weeks after the booster dose, we observed
382 differences in the neutralization capacity as compared to the D614G variant
383 (lineage B.1), which does not exhibit mutations in the RBD of the S1 protein
384 (**Figure 4 and table 3**). We previously reported that CoronaVac[®] is able to induce
385 neutralization against the Delta variant at 4 weeks after the second dose, although
386 to a lesser extent compared to the WT strain ¹⁴. Another study recently reported a
387 significant increase in the neutralizing capacity after a booster dose with
388 CoronaVac[®] for the Delta variant, as compared to the levels observed in volunteers
389 vaccinated with two doses ^{26,33}. Although we did not observe similar levels of
390 enhanced neutralization against the variants Delta after the booster dose using
391 pVNT (**Figure 4A**), the seropositivity against Delta variant is almost 100% (**Figure**
392 **4B**)³³. Here, we also show that a booster dose induces neutralization against the

393 variant Omicron, which has rapidly spread worldwide and is the predominant
394 circulating variant to date ³⁴. The high number of mutations described in the RBD of
395 this variant has been associated with increased evasion of neutralizing responses
396 in either unvaccinated or vaccinated subjects ^{34,35}. Although the neutralization
397 observed in subjects vaccinated with a booster dose of CoronaVac[®] is significantly
398 lower to the observed against the D614G variant, we observed a seropositivity of
399 76.7% following the booster, suggesting some degree of protection in most of the
400 vaccinees. In this sense, it has been reported that a heterologous schedule of
401 vaccination may induce a higher neutralization ability and a better neutralization
402 against variants of concern as Delta ³⁶ and Omicron¹⁶. In line with this, a
403 heterologous vaccination with CoronaVac[®] and a booster dose of Pfizer BNT162b2
404 showed a good neutralization titer against VOC Delta and Omicron, with respect to
405 the ancestral virus ¹⁶. Similarly, a comparison between heterologous and
406 homologous booster schedules after the vaccination with CoronaVac[®], shows an
407 increase in neutralization against the VOC Delta and Omicron¹⁵. There are
408 discrepancies between the results in neutralization titers, which can be attributed to
409 the neutralization assays performed and/or the study population; however,
410 important booster responses are observed in these studies, and seropositivity
411 reached after the booster dose of CoronaVac[®] against VOC are also similar ¹⁶.

412 In the case of the cellular response, this is the first report to characterize
413 CD4⁺ T cell responses following a booster dose of CoronaVac[®] against the
414 Omicron variant of SARS-CoV2. Previous studies using the same MP from VOC
415 evaluated here have shown that CD4⁺ T cells respond to VOC in a similar extent
416 as compared to the ancestral strain in individuals vaccinated with CoronaVac[®] ^{14,37}

417 and mRNA vaccines, which has been explained by the high conservation of T cell
418 epitopes. In this sense, the booster dose of CoronaVac[®] induces the expression of
419 CD4⁺ T cell activation markers and secretion of IFN- γ and IL-2 against the VOC
420 Delta and Omicron, which is comparable to the response generated against the
421 WT strain (**Figure 5**). In line with this, a recent study has shown that T cell
422 responses against the ancestral strain are cross-reactive against the Omicron
423 variant in convalescent individuals and volunteers vaccinated with Pfizer
424 BNT162b2 ³⁸, supporting the idea that the induction of T cell responses against the
425 ancestral strain may be protective against the Omicron variant.

426 Our report shows that the booster dose of CoronaVac[®] in a 0-28 days
427 schedule induces antibodies with neutralizing capacities, which are higher than the
428 levels observed at 2- and 4-weeks after the second dose, generating an increased
429 humoral response even in adults ≥ 60 years old. Besides this, our results suggest
430 that a third dose of CoronaVac[®] supports CD4⁺ T cell activation, which may confer
431 either protection or enhanced immune responses against the virus and prevent
432 severe disease following exposure to SARS-CoV-2 exposure. Importantly, the
433 humoral and cellular immune response promoted by a booster dose of CoronaVac
434 shows activity against Delta and Omicron variants and probably results in better
435 effectiveness of this vaccine during predominance of these VOC.

436

437 **Limitations**

438 This study presents several limitations, such as the reduced sample size for
439 the assays and the absence of data for neutralization against Omicron variant with

440 a conventional viral neutralization test. The assessment of total antibody response
441 against Spike proteins and other SARS-CoV-2 proteins would also add additional
442 information about the humoral immune response against SARS-CoV-2 after the
443 booster dose. Due to the limit of quantification of the technique, samples with
444 undetermined concentration at the lowest dilution tested (1:4) were assigned the
445 lower limit of quantification (16.4 IU) and other neutralization assays.

446

447 **Funding**

448 The CoronaVac03CL Study was funded by The Ministry of Health,
449 Government of Chile, the Confederation of Production and Commerce (CPC),
450 Chile and SINOVAC Biotech. NIH NIAID, under Contract 75N93021C00016,
451 supports AS and Contract 75N9301900065 supports AS, AG and DW. The
452 National Agency for Research and Development (ANID) through the Fondo
453 Nacional de Desarrollo Científico y Tecnológico (FONDECYT) grants N° 1190156
454 and N° 1211547 supports RSR and FVE, respectively. The Millennium Institute on
455 Immunology and Immunotherapy, ANID - Millennium Science Initiative Program
456 ICN09_016 (former P09/016-F) supports RSR, VFE, SMB, KA, PAG and AMK; The
457 Innovation Fund for Competitiveness FIC-R 2017 (BIP Code: 30488811-0)
458 supports SMB, PAG and AMK.

459 **Competing interests**

460 ZG and MW are SINOVAC Biotech employees and contributed to the
461 conceptualization of the study (clinical protocol and eCRF design) and did not
462 participate in the analysis or interpretation of the data presented in the manuscript.

463 A.S. is a consultant for Gritstone, Flow Pharma, Arcturus, Immunoscape,
464 CellCarta, OxfordImmunotech and Avalia. La Jolla Institute for Immunology (LJI)
465 has filed for patent protection for various aspects of T cell epitope and vaccine
466 design work. All other authors declare no conflict of interest.

467

468 **Acknowledgments**

469 We would like to thank the support of the Ministry of Health, Government of Chile;
470 Ministry of Science, Technology, Knowledge, and Innovation, Government of Chile;
471 The Ministry of Foreign Affairs, Government of Chile, and the Chilean Public Health
472 Institute (ISP). We also would like to thank Rami Scharf, Jessica White, Jorge
473 Flores and Miren Iturriza-Gomara from PATH for their support on experimental
474 design and discussion. Alex Cabrera and Sergio Bustos from the Flow Cytometry
475 Facility at Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile
476 for support with flow cytometry. We also thank the Vice Presidency of Research
477 (VRI), the Direction of Technology Transfer and Development (DTD), the Legal
478 Affairs Department (DAJ) of the Pontificia Universidad Católica de Chile. We are
479 also grateful to the Administrative Directions of the School of Biological Sciences
480 and the School of Medicine of the Pontificia Universidad Católica de Chile for their
481 administrative support. We would also like to thank the members of the
482 independent data safety monitoring committee (members in the SA) for their
483 oversight, and the subjects enrolled in the study for their participation and
484 commitment to this trial. This project has been funded in whole or in part with
485 Federal funds from the National Institute of Allergy and Infectious Diseases,

486 National Institutes of Health, Department of Health and Human Services, under
487 Contract No. Contract No. 75N9301900065 to A.S, A.G. and D.W.

488

489 Note: Members of the CoronaVac03CL Study Group are listed in the
490 Supplementary Appendix (SA).

491

492 **References**

- 493 1. Mallapaty S. WHO approval of Chinese CoronaVac COVID vaccine will be
494 crucial to curbing pandemic [Internet]. *Nature*. 2021 [cited 2021 Oct
495 6];594(7862):161–2. Available from:
496 <https://pubmed.ncbi.nlm.nih.gov/34089030/>
- 497 2. Q G, L B, H M, et al. Development of an inactivated vaccine candidate for
498 SARS-CoV-2. *Science* [Internet] 2020 [cited 2021 Oct 6];369(6499):77–81.
499 Available from: <https://pubmed.ncbi.nlm.nih.gov/32376603/>
- 500 3. Z W, Y H, M X, et al. Safety, tolerability, and immunogenicity of an
501 inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60
502 years and older: a randomised, double-blind, placebo-controlled, phase 1/2
503 clinical trial. *Lancet Infect Dis* [Internet] 2021 [cited 2021 Oct 6];21(6):803–
504 12. Available from: <https://pubmed.ncbi.nlm.nih.gov/33548194/>
- 505 4. Y Z, G Z, H P, et al. Safety, tolerability, and immunogenicity of an inactivated
506 SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised,
507 double-blind, placebo-controlled, phase 1/2 clinical trial. *Lancet Infect Dis*
508 [Internet] 2021 [cited 2021 Oct 6];21(2):181–92. Available from:
509 <https://pubmed.ncbi.nlm.nih.gov/33217362/>
- 510 5. SM B, K A, PA G, et al. Safety and Immunogenicity of an Inactivated SARS-
511 CoV-2 Vaccine in a Subgroup of Healthy Adults in Chile. *Clin Infect Dis*
512 [Internet] 2021 [cited 2021 Oct 9]; Available from:
513 <https://pubmed.ncbi.nlm.nih.gov/34537835/>
- 514 6. Sauré D, O’Ryan M, Torres JP, Zuniga M, Santelices E, Basso LJ. Dynamic
515 IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19

- 516 vaccines in Chile: a sentinel surveillance study. *Lancet Infect Dis* [Internet]
517 2021 [cited 2021 Oct 11];0(0). Available from:
518 <http://www.thelancet.com/article/S1473309921004795/fulltext>
- 519 7. Duarte LF, Gálvez NMS, Iturriaga C, et al. Immune Profile and Clinical
520 Outcome of Breakthrough Cases After Vaccination With an Inactivated
521 SARS-CoV-2 Vaccine. *Front Immunol* [Internet] 2021 [cited 2021 Oct
522 11];0:3884. Available from:
523 <https://www.frontiersin.org/articles/10.3389/fimmu.2021.742914/full>
- 524 8. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated
525 SARS-CoV-2 Vaccine in Chile. <https://doi.org/10.1056/NEJMoa2107715>
526 [Internet] 2021 [cited 2021 Oct 7];385(10):875–84. Available from:
527 <https://www.nejm.org/doi/full/10.1056/NEJMoa2107715>
- 528 9. Chile ha administrado más de 41 millones 980 mil dosis de vacuna contra
529 SARS-CoV-2 - Ministerio de Salud - Gobierno de Chile [Internet]. [cited 2021
530 Dec 10]; Available from: <https://www.minsal.cl/chile-ha-administrado-mas-de-41-millones-980-mil-dosis-de-vacuna-contra-sars-cov-2/>
531
- 532 10. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are
533 highly predictive of immune protection from symptomatic SARS-CoV-2
534 infection. *Nat Med* 2021 277 [Internet] 2021 [cited 2021 Oct 6];27(7):1205–
535 11. Available from: <https://www.nature.com/articles/s41591-021-01377-8>
- 536 11. Protection duration after vaccination or infection – Swiss National COVID-19
537 Science Task Force [Internet]. [cited 2021 Oct 6]; Available from:
538 [https://sciencetaskforce.ch/en/policy-brief/protection-duration-after-
539 vaccination-or-infection/](https://sciencetaskforce.ch/en/policy-brief/protection-duration-after-vaccination-or-infection/)

- 540 12. Pan H, Wu Q, Zeng G, et al. Immunogenicity and safety of a third dose, and
541 immune persistence of CoronaVac vaccine in healthy adults aged 18-59
542 years: interim results from a double-blind, randomized, placebo-controlled
543 phase 2 clinical trial. medRxiv [Internet] 2021 [cited 2021 Oct
544 6];2021.07.23.21261026. Available from:
545 <https://www.medrxiv.org/content/10.1101/2021.07.23.21261026v1>
- 546 13. Cao Y, Yisimayi A, Bai Y, et al. Humoral immune response to circulating
547 SARS-CoV-2 variants elicited by inactivated and RBD-subunit vaccines. *Cell*
548 *Res* 2021 317 [Internet] 2021 [cited 2021 Oct 8];31(7):732–41. Available
549 from: <https://www.nature.com/articles/s41422-021-00514-9>
- 550 14. Melo-González F, Soto JA, González LA, et al. Recognition of Variants of
551 Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated
552 Vaccine. *Front Immunol* [Internet] 2021;12. Available from:
553 <https://www.frontiersin.org/articles/10.3389/fimmu.2021.747830/full>
- 554 15. Clemens SAC, Weckx L, Clemens R, et al. Heterologous versus homologous
555 COVID-19 booster vaccination in previous recipients of two doses of
556 CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-
557 inferiority, single blind, randomised study. *Lancet* [Internet] 2022 [cited 2022
558 Jan 24];0(0). Available from:
559 <http://www.thelancet.com/article/S0140673622000940/fulltext>
- 560 16. Pérez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against
561 the SARS-CoV-2 Delta and Omicron variants following heterologous
562 CoronaVac plus BNT162b2 booster vaccination. *Nat Med* 2022 [Internet]
563 2022 [cited 2022 Jan 24];1–1. Available from:

- 564 <https://www.nature.com/articles/s41591-022-01705-6>
- 565 17. Acevedo M, Alonso-Palomares L, Pantano S, Pasteur I, Navarrete M, Soto-
566 Rifo R. Neutralization of the emerging SARS-CoV-2 variant Lambda by
567 antibodies elicited by inactivated virus and mRNA vaccines. 2021 [cited 2022
568 Jan 31]; Available from: <https://www.researchsquare.com>
- 569 18. Depto Inmunizaciones D, De Prevención D, Control, Y Enfermedades S,
570 Pública M de salud. DOSIS DE REFUERZO EN LA CAMPAÑA DE
571 VACUNACIÓN CONTRA SARS-COV-2 EN CHILE. 2021 [cited 2021 Oct
572 6]; Available from: <https://www.minsal.cl/wp->
- 573 19. Immunization Campaign against SARS-CoV-2 Early estimates of the
574 effectiveness of booster shots in Chile [Internet]. 2021 [cited 2021 Dec
575 10]; Available from: [https://www.minsal.cl/wp-content/uploads/2021/10/2021-](https://www.minsal.cl/wp-content/uploads/2021/10/2021-10-07-EFECTIVIDAD-DOSIS-DE-REFUERZO_ENG.pdf)
576 [10-07-EFECTIVIDAD-DOSIS-DE-REFUERZO_ENG.pdf](https://www.minsal.cl/wp-content/uploads/2021/10/2021-10-07-EFECTIVIDAD-DOSIS-DE-REFUERZO_ENG.pdf)
- 577 20. World medical association. World Medical Association declaration of
578 Helsinki: Ethical principles for medical research involving human subjects
579 [Internet]. JAMA - J. Am. Med. Assoc. 2013 [cited 2021 Oct 6];310(20):2191–
580 4. Available from: <https://pubmed.ncbi.nlm.nih.gov/24141714/>
- 581 21. WHO/BS.2020.2403 Establishment of the WHO International Standard and
582 Reference Panel for anti-SARS-CoV-2 antibody [Internet]. [cited 2021 Oct
583 8]; Available from: [https://www.who.int/publications/m/item/WHO-BS-](https://www.who.int/publications/m/item/WHO-BS-2020.2403)
584 [2020.2403](https://www.who.int/publications/m/item/WHO-BS-2020.2403)
- 585 22. Acevedo ML, Alonso-Palomares L, Bustamante A, et al. Infectivity and
586 immune escape of the new SARS-CoV-2 variant of interest Lambda.
587 medRxiv [Internet] 2021 [cited 2022 Jan 24];2021.06.28.21259673. Available

- 588 from: <https://www.medrxiv.org/content/10.1101/2021.06.28.21259673v1>
- 589 23. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to
590 SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and
591 Unexposed Individuals. *Cell* 2020;181(7):1489-1501.e15.
- 592 24. Lumley SF, O'Donnell D, Stoesser NE, et al. Antibody Status and Incidence
593 of SARS-CoV-2 Infection in Health Care Workers.
594 <https://doi.org/10.1056/NEJMoa2034545> [Internet] 2020 [cited 2021 Oct
595 8];384(6):533–40. Available from:
596 <https://www.nejm.org/doi/10.1056/NEJMoa2034545>
- 597 25. Sabino EC, Buss LF, Carvalho MPS, et al. Resurgence of COVID-19 in
598 Manaus, Brazil, despite high seroprevalence. *Lancet* 2021;397(10273):452–
599 5.
- 600 26. Wang K, Cao Y, Zhou Y, et al. A third dose of inactivated vaccine augments
601 the potency, breadth, and duration of anamnestic responses against SARS-
602 CoV-2. *medRxiv* [Internet] 2021 [cited 2021 Oct 8];2021.09.02.21261735.
603 Available from:
604 <https://www.medrxiv.org/content/10.1101/2021.09.02.21261735v1>
- 605 27. Bar-On YM, Goldberg Y, Mandel M, et al. BNT162b2 vaccine booster dose
606 protection: A nationwide study from Israel. *medRxiv* [Internet] 2021 [cited
607 2021 Oct 8];2021.08.27.21262679. Available from:
608 <https://www.medrxiv.org/content/10.1101/2021.08.27.21262679v1>
- 609 28. Seyahi E, Bakhdiyarli G, Oztas M, et al. Antibody response to inactivated
610 COVID-19 vaccine (CoronaVac) in immune-mediated diseases: a controlled
611 study among hospital workers and elderly. *Rheumatol Int* 2021 418 [Internet]

- 612 2021 [cited 2021 Oct 8];41(8):1429–40. Available from:
613 <https://link.springer.com/article/10.1007/s00296-021-04910-7>
- 614 29. Widge AT, Roupheal NG, Jackson LA, et al. Durability of Responses after
615 SARS-CoV-2 mRNA-1273 Vaccination.
616 <https://doi.org/10.1056/NEJMc2032195> [Internet] 2020 [cited 2021 Oct
617 8];384(1):80–2. Available from:
618 <https://www.nejm.org/doi/full/10.1056/NEJMc2032195>
- 619 30. Li M, Yang J, Wang L, et al. A booster dose is immunogenic and will be
620 needed for older adults who have completed two doses vaccination with
621 CoronaVac: a randomised, double-blind, placebo-controlled, phase 1/2
622 clinical trial. medRxiv [Internet] 2021 [cited 2021 Oct
623 8];2021.08.03.21261544. Available from:
624 <https://www.medrxiv.org/content/10.1101/2021.08.03.21261544v1>
- 625 31. Mateus J, Dan JM, Zhang Z, et al. Low-dose mRNA-1273 COVID-19 vaccine
626 generates durable memory enhanced by cross-reactive T cells. *Science* (80-
627) [Internet] 2021 [cited 2021 Nov 11];374(6566). Available from:
628 <https://www.science.org/doi/abs/10.1126/science.abj9853>
- 629 32. Guerrera G, Picozza M, D’Orso S, et al. BNT162b2 vaccination induces
630 durable SARS-CoV-2 specific T cells with a stem cell memory phenotype.
631 *Sci Immunol* [Internet] 2021 [cited 2021 Nov 11];Available from:
632 <https://www.science.org/doi/abs/10.1126/sciimmunol.abl5344>
- 633 33. Cao Y, Hao X, Wang X, et al. Humoral immunogenicity and reactogenicity of
634 CoronaVac or ZF2001 booster after two doses of inactivated vaccine. *Cell
635 Res* 2021 [Internet] 2021 [cited 2021 Dec 10];1–3. Available from:

- 636 <https://www.nature.com/articles/s41422-021-00596-5>
- 637 34. Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the
638 SARS-CoV-2 Omicron variant in southern Africa. *Nat* 2022 [Internet] 2022
639 [cited 2022 Jan 31];1–10. Available from:
640 <https://www.nature.com/articles/s41586-022-04411-y>
- 641 35. Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly
642 resistant against antibody-mediated neutralization: Implications for control of
643 the COVID-19 pandemic. *Cell* [Internet] 2021 [cited 2022 Jan 25]; Available
644 from: <https://linkinghub.elsevier.com/retrieve/pii/S0092867421014951>
- 645 36. Ai J, Zhang H, Zhang Q, et al. Recombinant protein subunit vaccine booster
646 following two-dose inactivated vaccines dramatically enhanced anti-RBD
647 responses and neutralizing titers against SARS-CoV-2 and Variants of
648 Concern. *Cell Res* 2021 [Internet] 2021 [cited 2021 Dec 10];1–4. Available
649 from: <https://www.nature.com/articles/s41422-021-00590-x>
- 650 37. A T, J S, N M, et al. Impact of SARS-CoV-2 variants on the total CD4 + and
651 CD8 + T cell reactivity in infected or vaccinated individuals. *Cell reports Med*
652 [Internet] 2021 [cited 2021 Oct 25];2(7). Available from:
653 <https://pubmed.ncbi.nlm.nih.gov/34230917/>
- 654 38. Gao Y, Cai C, Grifoni A, et al. Ancestral SARS-CoV-2-specific T cells cross-
655 recognize the Omicron variant. *Nat Med* 2022 [Internet] 2022 [cited 2022 Jan
656 25];1–9. Available from: [https://www.nature.com/articles/s41591-022-01700-](https://www.nature.com/articles/s41591-022-01700-x)
657 [x](https://www.nature.com/articles/s41591-022-01700-x)
- 658
- 659

660 **Figures legends**

661

662 **Figure 1: Study profile, enrolled volunteers, and cohort included in the study**

663 **by November 11th, 2021. A.** From the one hundred and eighty-six vaccinated

664 individuals that received the booster dose, seventy-seven volunteers that received

665 two doses of CoronaVac® in a 28 days interval (0-28 days schedule of

666 vaccination), were selected from the center assigned for the immunogenicity study.

667 Seventy-seven volunteers were tested for neutralizing antibodies by sVNT, sixty-

668 two were selected to analyze neutralizing antibodies by cVNT and forty were

669 selected to analyze cellular immunity. Analyses for immunity against SARS-CoV-2

670 variants were performed in 30 volunteers for sVNT, pVNT and T cells assays. **B.**

671 Timeline of 0–28 days schedule of vaccination and booster dose immunization.

672 Text in red denotes timepoints at which blood draws occurred.

673

674 **Figure 2: Quantification of circulating antibodies inhibiting the interaction**

675 **between the S1-RBD and hACE2 and in live SARS-CoV-2 in volunteers that**

676 **received the booster dose of CoronaVac®. A-C.** Inhibiting antibodies were

677 detected in serum of volunteers immunized with CoronaVac® using a surrogate

678 Viral Neutralization Test (sVNT), which quantifies the interaction between S1-RBD

679 and hACE2 on ELISA plates. Results were obtained from a total of seventy-seven

680 volunteers (**A**), thirty-six of them were adults between 18-59 years old (**B**), and

681 forty-one of them were ≥ 60 years old (**C**). Data is represented as WHO arbitrary

682 units/mL, the numbers above each set of individual data points show the

683 Geometric Mean Units (GMU), the error bars indicate the 95% CI, and the number

684 at the right represents the fold increase of the GMU four weeks after the third dose
685 as compared with the respective times after administration of the second dose. **D-**
686 **F.** Neutralizing antibodies were detected in serum of volunteers that received a
687 booster dose of CoronaVac® twenty weeks after the second dose, using a
688 conventional Viral Neutralization Test (cVNT), which quantifies the reduction of
689 cytopathic effect (CPE) in Vero E6 cells infected with SARS-CoV-2. Results were
690 obtained from 62 volunteers (**D**), 30 of them were adults between 18-59 years old
691 (**E**), and 32 of them were ≥ 60 years old (**F**). Data are expressed as the reciprocal
692 of the highest serum dilution preventing 100% cytopathic effect, the numbers
693 above each set of individual data points show the Geometric Mean Titer (GMT),
694 the error bars indicate the 95% CI, and the number at the right represents the fold
695 increase of the GMU the third dose + 4 weeks as compared with the respective
696 times after administration of the second dose. CI were not adjusted for multiplicity
697 and should not be used for inference. A repeated measures One-Way ANOVA test
698 assessed statistical differences to compare all times against 3rd dose + four weeks.
699 **** $p < 0.0001$.

700

701 **Figure 3: Changes in activation-induced markers (AIMs) expression in CD4⁺ T**
702 **cells and in the number of IFN- γ -secreting cells specific for SARS-CoV-2 after**
703 **a booster dose of CoronaVac®. A-C.** AIM⁺ CD4⁺ T cells were quantified in
704 peripheral blood mononuclear cells of volunteers that received a booster dose of
705 CoronaVac® twenty weeks after the second dose by flow cytometry, upon
706 stimulation with mega-pools of peptides derived from SARS-CoV-2 proteins. The

707 percentage of activated AIM⁺ CD4⁺ T cells (OX40⁺, CD137⁺) were determined upon
708 stimulation for 24h with MP-S+R in samples obtained at pre-immune, two weeks
709 after the second dose, four weeks after the second dose, twenty weeks the second
710 dose, and four weeks after the booster dose. Data from flow cytometry was
711 normalized against DMSO and analyzed separately by a Friedman test against the
712 booster dose. Results were obtained from a total of forty volunteers (**A**), twenty-
713 one were of them were adults between 18-59 years old (**B**), and nineteen of them
714 were ≥ 60 years old (**C**). Changes in the secretion of IFN- γ were quantified as the
715 number of Spot Forming Cells (SFCs) in peripheral blood mononuclear cells of
716 volunteers that received a booster dose of CoronaVac® 20 weeks after the second
717 dose. **D-F**. Data was obtained upon stimulation with MP-S+R for 48h in samples
718 obtained at pre-immune, two weeks after the second dose, four weeks after the
719 second dose, twenty weeks the second dose, and four weeks after the booster
720 dose. Results were obtained from a total of 40 volunteers (**D**), 21 were of them
721 were adults between 18-59 years old (**E**), and 19 of them were ≥ 60 years old (**F**).
722 Data from ELISPOT were analyzed separately by Friedman test against the
723 booster dose *p<0.05; **p<0.005; ***p< < 0.001; ****p<0.0001.

724

725 **Figure 4: Quantification of circulating neutralizing antibodies against SARS-**
726 **CoV-2 variants in volunteers that received the booster dose of CoronaVac®.**

727 **A.** Neutralizing antibodies were detected in the serum of thirty volunteers, four
728 weeks after the booster dose of CoronaVac®, using a pseudotyped virus
729 neutralization test (pVNT). Data are expressed as the reciprocal of the highest

730 dilution preventing 80% of the infection (ID80). Numbers above the bars show the
731 Mean, and the error bars indicate the 95% CI. The number at the right represents
732 the fold decrease of the GMT four weeks after the booster dose as compared with
733 the response of D614G **B**. Seropositivity rate of neutralizing antibodies is shown for
734 each time point analyzed. Numbers above the bars show the percentage of
735 seropositivity rate in the respective graphs. Numbers above the bars show the
736 percentage of seropositivity rate in the respective graphs. A repeated measures
737 One-Way ANOVA test assessed statistical differences of the GMT to compare
738 each variant against D614G. * $p < 0.05$; *** $p < 0.001$; **** $p < 0.0001$

739

740

741 **Figure 5: A booster dose of CoronaVac® induce changes in the number of**
742 **IFN- γ -secreting cells and in activation-induced markers (AIMs) expression in**
743 **CD4⁺ T cells specific for the Spike protein of SARS-CoV-2 variants. A.**

744 Changes in the secretion of IFN- γ , determined as the number of Spot Forming
745 Cells (SFCs) were determined. Data was obtained upon stimulation of PBMC with
746 MP-S of variant of concern of SARS-CoV-2 for 48h in samples obtained four weeks
747 after the booster dose. Data shown represent mean + 95%CI. Data from thirty
748 volunteers were analyzed at four weeks after the booster dose to compare among
749 the MP-S of the variant of concern. Data from ELISPOT were analyzed separately
750 by Friedman test against the WT MP-S. No significant differences were obtained.

751 **B.** AIM⁺ CD4⁺ T cells were quantified in peripheral blood mononuclear cells of thirty
752 volunteers four weeks after that received a booster dose of CoronaVac® by flow

753 cytometry, upon stimulation with mega-pools of peptides derived from proteins of
754 variant of concern of SARS-CoV-2. The percentage of activated AIM⁺ CD4⁺ T cells
755 (OX40⁺, CD137⁺) were determined upon stimulation for 24h with MP-S+R in
756 samples obtained four weeks after the booster dose. Data shown represent mean
757 + 95%CI. Data from flow cytometry was normalized against DMSO. No significant
758 differences were obtained between WT and the variant MP stimulation.
759

760 **Table**

761 **Table 1: Demographic and clinical data of seventy-seven volunteers**
 762 **analyzed.**

763
 764

	Age group	AHT N (%)	AR N (%)	MD N (%)	Obesity N (%)	Insulin resistance N (%)	COPD N (%)	HT N (%)
Female sex N (%)	41 (53.2)	11 (14.3)	8 (10.4)	1 (1.3)	6 (7.8)	6 (7.8)	3 (3.9)	7 (9.1)
18-59 years old	18 (23.4)	3 (3.9)	6 (7.8)	0	2 (2.6)	3 (3.9)	0	2 (2.6)
≥60 years old	23 (30.0)	8 (10.4)	2 (2.6)	1 (1.3)	4 (5.2)	3 (3.9)	3 (3.9)	5 (6.5)
Male sex N (%)	36 (46.8)	11 (14.3)	8 (10.4)	3 (3.9)	11 (14.3)	1 (1.3)	0	1 (1.3)
18-59 years old	17 (22.0)	4 (5.2)	4 (5.2)	2 (2.6)	4 (5.2)	0	0	0
≥60 years old	19 (24.6)	7 (9.1)	4 (5.2)	1 (1.3)	7 (9.1)	1 (1.3)	0	1 (1.3)

765 *Arterial hypertension: AHT; Chronic obstructive pulmonary disease: COPD; Mellitus diabetes: MD;*
 766 *Hypothyroidism: HT; Allergic rhinitis: AR*
 767

768 **Table 2: Seropositivity rates, Geometric Mean Titer (GMT), and Geometric**
 769 **Mean Units (GMU) of circulating neutralizing antibodies against SARS-CoV-2**
 770 **RBD.**

Methodology	Age group	Indicators	2 nd dose + 2 weeks	2 nd dose + 4 weeks	2 nd dose + 20 weeks	3 rd dose + 4 weeks
sVNT	Total Vaccine	Seropositivity n/N	72/77	73/77	38/77	75/77
		(%)	93.5	94.8	49.4	97.4
		GMU	168.0	124.8	39.0	499.4
		95% CI	126.8-222.5	96.3-161.7	32.4-47.0	370.6-673.0
		GMT	25.8	16.6	3.5	53.0
		95% CI	19.5-34.2	13.1-21.0	3.0-4.1	40.8-68.8
	18-59	Seropositivity n/N	35/36	36/36	24/36	36/36
		(%)	97.2	97.2	66.7	100
		GMU	220.2	155.0	48.9	918.8
		95% CI	150.7-321.7	108.0-222.6	37.6-63.5	623.4-1354
		GMT	33.3	19.1	4.3	82.8
		95% CI	23.4-47.3	14.0-26.1	3.4-5.4	59.7-114.8
	≥60	Seropositivity n/N	38/41	39/42	15/42	40/42
		(%)	90.5	92.9	35.7	95.2
		GMU	134.1	104.1	32.4	300.5
		95% CI	89.2-201.6	71.8-151.0	25.1-41.8	203.5-443.6
		GMT	20.8	14.7	2.4	36.5
		95% CI	13.6-31.9	10.3-21.0	2.4-3.5	25.3-52.7
cVNT	Total Vaccine	Seropositivity n/N	49/62	51/62	44/62	62/72
		(%)	79.0	82.3	71.0	100
		GMT	12.8	13.5	8.3	89.5
		95% CI	8.8-18.5	9.6-19.2	5.6-12.2	64.0-125.2
	18-59	Seropositivity n/N	25/30	27/30	23/30	30/30
		(%)	83.3	90.0	76.7	100

		GMT	17.5	18.8	14.2	176.9
		95% CI	9.8-31.3	11.2-31.7	7.1-28.4	111.7-280.1
	≥60	Seropositivity n/N	24/32	24/32	21/32	32/32
		(%)	75.0	75.0	65.6	100
		GMT	9.5	9.9	5.0	47.3
		95% CI	5.8-15.4	6.2-15.8	3.5-7.0	32.1-69.5

771 *sVNT: Surrogate Virus Neutralization; cVNT: Conventional Virus Neutralization; GMT: Geometric*
772 *mean titer; GMU: Geometric mean units.*

773 **Table 3: Seropositivity rates, Geometric Mean Titer (GMT) of circulating**
774 **neutralizing antibodies against SARS-CoV-2 RBD of D614G and variants of**
775 **concern (Delta and Omicron).**

776

	Variant	D614G	Delta (B.1.617.2)	Omicron (B.1.1.529)
pVNT	Indicators	3rd dose + 4 weeks	3rd dose + 4 weeks	3rd dose + 4 weeks
	Seropositivity n/N	30/30	28/30	23/30
	(%)	100	93.3	76.6
	GMT	241.8	159.2	50.7
	95% CI	155.7- 375.6	99.1-256.0	30.4-84.8

777

778 *GMT: Geometric mean titer.*

779

780

Figure 1




Figure 2





Figure 3





Figure 4




Figure 5

